Clinical Trials | November 26, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Cagrilintide represents a novel approach to obesity management
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Subscribe To Our Newsletter & Stay Updated
